PRO118 WHAT IS THE IMPACT OF ORPHAN DRUG RE-ASSESSMENTS IN GERMANY ON THEIR ADDITIONAL BENEFIT AND PRICE?
Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.2448
https://www.valueinhealthjournal.com/article/S1098-3015(19)34826-0/fulltext
Section Title :
Section Order :
12143
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)34826-0&doi=10.1016/j.jval.2019.09.2448